Key Takeaways BAYRY says asundexian met primary efficacy and safety endpoints in the OCEANIC-STROKE study.The drug cut ischemic stroke risk versus placebo when added to antiplatelet therapy.BAYRY plans global filings after results showed no rise in ISTH major bleeding with asundexian.Bayer AG (BAYRY) announced that pipeline candidate asundexian met primary efficacy and safety endpoints in late-stage OCEANIC-STROKE Study in secondary stroke prevention.Results from the study showed that asundexian 50 mg once ...

The Food and Drug Administration (FDA) on Wednesday granted accelerated approval to Bayer AG‘s (OTC:BAYRY) Hyrnuo (sevabertinib) for adults with a specific type of advanced lung cancer.The approval covers locally advanced or metastatic, non-squamous non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations and who have received a prior systemic therapy.The FDA also approved the Oncomine Dx Target Test (Life Technologies Corporation) as a companion diagnostic device to aid ...